Loading...

We've got a brand new version of Simply Wall St! Try it out

Cannara Biotech

CNSX:LOVE
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LOVE
CNSX
CA$120M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Cannara Biotech Inc. operates indoor cannabis cultivation facility in Canada. The last earnings update was 332 days ago. More info.


Add to Portfolio Compare Print
  • Cannara Biotech has significant price volatility in the past 3 months.
LOVE Share Price and Events
7 Day Returns
0%
CNSX:LOVE
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:LOVE
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
LOVE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cannara Biotech (LOVE) 0% 13.3% 6.3% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on LOVE.
  • No trading data on LOVE.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Cannara Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cannara Biotech. This is due to cash flow or dividend data being unavailable. The share price is CA$0.17.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cannara Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cannara Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:LOVE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-08-31) in CAD CA$-0.01
CNSX:LOVE Share Price ** CNSX (2019-09-20) in CAD CA$0.17
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cannara Biotech.

CNSX:LOVE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:LOVE Share Price ÷ EPS (both in CAD)

= 0.17 ÷ -0.01

-14.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannara Biotech is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Cannara Biotech is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Cannara Biotech's expected growth come at a high price?
Raw Data
CNSX:LOVE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cannara Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cannara Biotech's assets?
Raw Data
CNSX:LOVE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-08-31) in CAD CA$0.03
CNSX:LOVE Share Price * CNSX (2019-09-20) in CAD CA$0.17
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:LOVE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:LOVE Share Price ÷ Book Value per Share (both in CAD)

= 0.17 ÷ 0.03

5.5x

* Primary Listing of Cannara Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannara Biotech is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Cannara Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cannara Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cannara Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cannara Biotech expected to grow at an attractive rate?
  • Unable to compare Cannara Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cannara Biotech's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Cannara Biotech's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:LOVE Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:LOVE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:LOVE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-08-31 1 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cannara Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Cannara Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:LOVE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cannara Biotech Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:LOVE Past Financials Data
Date (Data in CAD Millions) EPS *
2018-08-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cannara Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Cannara Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Cannara Biotech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cannara Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cannara Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cannara Biotech performed over the past 5 years?

  • Cannara Biotech's last earnings update was 332 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cannara Biotech's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cannara Biotech does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Cannara Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cannara Biotech's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cannara Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cannara Biotech Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:LOVE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-08-31 0.87 -4.23 3.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cannara Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cannara Biotech has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cannara Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cannara Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cannara Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cannara Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cannara Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cannara Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cannara Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cannara Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cannara Biotech Company Filings, last reported 1 year ago.

CNSX:LOVE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-08-31 14.74 12.51 12.90
  • Cannara Biotech's level of debt (84.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Cannara Biotech's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Cannara Biotech's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Cannara Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cannara Biotech has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cannara Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cannara Biotech dividends.
If you bought CA$2,000 of Cannara Biotech shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cannara Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cannara Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:LOVE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cannara Biotech has not reported any payouts.
  • Unable to verify if Cannara Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cannara Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cannara Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cannara Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cannara Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cannara Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cannara Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zohar Krivorot
COMPENSATION CA$0
AGE 42
CEO Bio

Mr. Zohar Krivorot is Founder, President, Chief Executive Officer and Director at Cannara Biotech Inc. A successful entrepreneur, Mr. Krivorot has founded, advised, invested and sold numerous companies, including Voice over IP application platform 911ENABLE™. Mr. Krivorot has been recognized as a top leader and innovator by a number of sources, including Deloitte Technology Fast 50™ fastest growing technology companies in Canada. He is actively involved with early-stage companies as an advisor and board member. Mr. Krivorot is also a certified commercial pilot.

CEO Compensation
  • Insufficient data for Zohar to compare compensation growth.
  • Insufficient data for Zohar to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Zohar Krivorot

TITLE
Founder
AGE
42

Lennie Ryer

TITLE
VP of Finance & CFO
COMPENSATION
CA$300K
AGE
58
TENURE
1.2 yrs

Barry Laxer

TITLE
Chief Operating Officer
TENURE
0.1 yrs

Julia Bouvet

TITLE
Chief of Staff
Board of Directors

Zohar Krivorot

TITLE
Founder
AGE
42

Derek Stern

TITLE
Director
AGE
52

Amy Satov

TITLE
Director
AGE
50

Thomas Fairfull

TITLE
Director
AGE
70

Jack Kay

TITLE
Director
AGE
79
TENURE
0.4 yrs

Sara May

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
15. Aug 19 Buy Javaa Private Equity Inc Company 15. Aug 19 15. Aug 19 125,000 CA$0.16 CA$18,914
09. Aug 19 Buy Javaa Private Equity Inc Company 09. Aug 19 09. Aug 19 422,000 CA$0.15 CA$62,203
08. Aug 19 Buy Javaa Private Equity Inc Company 07. Aug 19 07. Aug 19 345,000 CA$0.14 CA$47,300
14. Mar 19 Buy Javaa Private Equity Inc Company 13. Mar 19 13. Mar 19 1,282,000 CA$0.19 CA$238,324
14. Mar 19 Buy Lennie Ryer Individual 13. Mar 19 13. Mar 19 45,000 CA$0.18 CA$8,100
31. Jan 19 Sell Donal Carroll Individual 30. Jan 19 30. Jan 19 -500,000 CA$0.20 CA$-98,500
X
Management checks
We assess Cannara Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cannara Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Cannara Biotech (CNSX:LOVE) Seems To Be Really Weighed Down By Its Debt

See our latest analysis for Cannara Biotech What Is Cannara Biotech's Net Debt? … Cannara Biotech boasts net cash, so it's fair to say it does not have a heavy debt load! … But you can't view debt in total isolation; since Cannara Biotech will need earnings to service that debt.

Simply Wall St -

Company Info

Description

Cannara Biotech Inc. operates indoor cannabis cultivation facility in Canada. The company was founded in 2018 and is headquartered in St-Laurent, Canada.

Details
Name: Cannara Biotech Inc.
LOVE
Exchange: CNSX
Founded: 2018
CA$120,151,019
706,770,705
Website: http://cannara.ca
Address: Cannara Biotech Inc.
333 Decarie boulevard,
Suite 200,
St-Laurent,
Quebec, H4N 3M9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX LOVE Common Shares Canadian National Stock Exchange CA CAD 14. Jan 2019
OTCPK LOVF.F Common Shares Pink Sheets LLC US USD 14. Jan 2019
DB 8CB Common Shares Deutsche Boerse AG DE EUR 14. Jan 2019
Number of employees
Current staff
Staff numbers
13
Cannara Biotech employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:47
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2018/10/25
Last earnings reported: 2018/08/31
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.